Analyst Price Targets — LYRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 7, 2024 3:03 am | Dennis Ding | Jefferies | $0.50 | $0.52 | StreetInsider | Jefferies Downgrades Lyra Therapeutics (LYRA) to Hold |
Latest News for LYRA
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Monday.
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company's lead product candidate for the treatment of chronic rhinosinusitis (CRS).
Lyra Therapeutics, Inc. (NASDAQ: LYRA - Get Free Report)'s share price was up 0.3% on Friday. The stock traded as high as $3.70 and last traded at $3.59. Approximately 32,339 shares changed hands during trading, a decline of 4% from the average daily volume of 33,546 shares. The stock had previously closed at $3.58. Analysts
Lyra Therapeutics, Inc. (NASDAQ: LYRA - Get Free Report)'s share price was up 4.5% on Wednesday. The stock traded as high as $4.32 and last traded at $4.19. Approximately 48,758 shares traded hands during mid-day trading, a decline of 48% from the average daily volume of 94,587 shares. The stock had previously closed at $4.01.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LYRA.
U.S. House Trading
No House trades found for LYRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.